Both routes deliver an oil-based depot that releases testosterone gradually. The hormone reaching the bloodstream is identical, and the receptors it acts on do not know where it entered. What differs is the tissue holding the depot, how quickly it empties, and therefore the shape of the concentration curve between administrations.
Why testosterone is given as an ester at all
Testosterone on its own clears too quickly to be practical as an injection. Attaching a fatty acid chain and suspending the result in oil creates a depot that releases slowly as enzymes cleave the ester back to testosterone. Cypionate, enanthate, and undecanoate differ in chain length, and longer chains release more slowly. That chemistry, rather than the route, explains most of the difference between how long these products last.
Once the ester is cleaved, what circulates is testosterone. There is no separate pharmacology for a subcutaneous molecule versus an intramuscular one. The route influences the rate at which the depot is drawn into circulation, not what happens afterward.
Muscle and subcutaneous tissue empty a depot differently
Skeletal muscle carries a denser blood supply than the fat layer beneath the skin. An oil depot placed in muscle is therefore absorbed comparatively fast, producing a higher early concentration followed by a longer decline. A depot in subcutaneous tissue is drawn up more slowly, which flattens the curve.
That flattening is the design rationale behind the one injectable testosterone product approved in the United States for subcutaneous use. Xyosted is a testosterone enanthate auto-injector approved under NDA 209863 and labeled for subcutaneous administration, with the label directing that intramuscular and intravascular routes be avoided. Its development premise was a lower peak-to-trough ratio than the intramuscular esters produce.
What the label permits versus what is done
Precision matters here because the two are frequently conflated. Testosterone cypionate injection is labeled for intramuscular use only. Generic testosterone enanthate solution carries the same intramuscular route. Testosterone undecanoate, sold as Aveed, is intramuscular only and is dispensed under a restricted program with a boxed warning covering pulmonary oil microembolism reactions and anaphylaxis.
When a cypionate vial is given under the skin, that is off-label practice. It is documented in the clinical literature and prescribers do it. Describing it as an approved subcutaneous option would be wrong. Only the enanthate auto-injector holds that approval.
What the comparative evidence actually measured
The evidence base is smaller than the confidence with which the topic is usually discussed. A Journal of Urology study of 234 hypogonadal men set intramuscular cypionate against the subcutaneous enanthate auto-injector and measured total testosterone, estradiol, hematocrit, and prostate specific antigen at baseline and again after twelve weeks. Trough total testosterone rose significantly in both groups, and once covariates were accounted for, the delivery method was not independently associated with total testosterone. The auto-injector was independently associated with lower post-treatment estradiol and hematocrit. Neither method produced a significant prostate specific antigen elevation.
A separate crossover pilot in the American Journal of Health-System Pharmacy followed fourteen participants in a gender-affirming therapy setting who moved from intramuscular administration to subcutaneous. Dose-normalized total testosterone exposure was comparable between the two phases, and hemoglobin and alanine transaminase did not change significantly. The authors reported wide variation both within and between individuals, and fourteen people is a pilot, not a definitive answer.
| Property | Intramuscular depot | Subcutaneous depot |
|---|---|---|
| Tissue blood supply | Denser | Sparser |
| Absorption pattern | Faster early release | Slower, flatter release |
| Approved US injectables | Cypionate, enanthate, undecanoate | Enanthate auto-injector only |
| Total testosterone achieved | Comparable in published comparisons | Comparable in published comparisons |
| Estradiol and hematocrit | Higher in the larger comparison | Lower in the larger comparison |
| Evidence volume | Decades of clinical use | Limited, mostly recent |
What results the route does not change
Testosterone therapy is treatment for diagnosed hypogonadism. Professional guidance from the Endocrine Society and from consensus panels covering men with type 2 diabetes and functional hypogonadism frames the goal as correcting a deficiency and relieving the symptoms attributable to it. Every label in the class also states that safety and efficacy in men with age-related hypogonadism have not been established.
That framing is where credible providers line up, whatever their route mix. Ro, Hims and Hers, Henry Meds, and HealthRX, which markets its testosterone replacement therapy program around a documented diagnosis and scheduled labs, are distinct companies competing on service rather than on any shortcut past the diagnostic step. A program willing to skip that step is the one to treat with caution.
Neither route makes testosterone therapy something else. It does not become a performance aid, a body composition program, or a general vitality treatment because it is administered under the skin. Published work on the growth in non-prescribed androgen use makes the same point from the opposite direction, describing the fertility consequences that follow when testosterone is used outside a diagnosed indication.
Where the route decision is actually made
In practice the route is chosen by whoever is prescribing, on the basis of which product they can dispense, what the label supports, and the individual’s history. Direct-to-consumer men’s health services differ widely in that respect, and providers such as Hone Health, Marek Health, Defy Medical, and FormBlends do not all offer the same product formats or the same review cadence. Learning which product a program actually dispenses is more informative than a general claim about routes. Whatever the format, testosterone is a Schedule III controlled substance and requires a valid prescription.
Frequently asked questions
Does one route produce higher testosterone levels?
Published comparisons found similar total testosterone once the analysis accounted for other factors. The difference sits in the shape of the curve rather than in the average, with the intramuscular depot producing a more pronounced early peak and the subcutaneous depot a flatter profile.
Is a flatter curve automatically better?
Not automatically. Lower estradiol and hematocrit were seen with the flatter profile in the larger comparison, which is a plausible benefit, but the study was not designed to show that this translates into better long-term outcomes. It is a reasonable point in favor rather than a settled conclusion.
Why is only one product approved for subcutaneous use?
Because approval attaches to a specific product and the studies submitted for it, not to a route in general. The enanthate auto-injector was developed and reviewed for subcutaneous administration. The older vials were approved decades earlier for intramuscular use and were never relabeled.
How long before results appear?
That depends on which symptom is being tracked, and the honest answer is that different effects follow different timelines. Guidelines describe reassessment at defined intervals with laboratory confirmation rather than a single expected date, and interpreting those results is part of what follow-up is for.
Does the route change fertility effects?
No. Suppression of the hypothalamic-pituitary-gonadal axis follows from exogenous testosterone in the bloodstream, so it happens with either route. Anyone who may want children should raise it before starting rather than treating it as a later problem.
